Skip to main content
placeholder image

A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Lee, D. H., Roohullah, A., Cho, B. C., Lemech, C. R., de Souza, P. L., Millward, M., . . . Han, J. -Y. (2022). A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 3105. doi:10.1200/jco.2022.40.16_suppl.3105

Web Of Science Accession Number


Start Page


  • 3105

End Page


  • 3105

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Lee, D. H., Roohullah, A., Cho, B. C., Lemech, C. R., de Souza, P. L., Millward, M., . . . Han, J. -Y. (2022). A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 3105. doi:10.1200/jco.2022.40.16_suppl.3105

Web Of Science Accession Number


Start Page


  • 3105

End Page


  • 3105

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication